Skip to main content
OpenTrials
Completed

NCT Number: NCT07461389

Effects of Pre-procedure and Intra-procedure Simethicone and Dicyclomine Administration in Improving Quality of Endoscopic Reterograde Cholangipancreaticography (ERCP)

Endoscopic Reterograde Cholangiopancreatography is widely used to diagnose and treat hepatobiliary disorders. Ampullary cannulation is an essential step and good mucosal visibility improves procedural efficiency.

Objective of the study: Our study aims to investigate the effects of Pre-procedural and intra-procedural administration of Semithicone as a defoaming agent and Dicylomine in reducing duodenal contractions.

Methodology: A randomized, double blind, controlled, trial will be conducted at Combined Military Hospital, Lahore after obtaining informed consent. Data will be prospectively collected over a period of 6 months. Patients will be randomized into three groups using block randomization and split into 3 groups i.e: Group 1: control (no intervention), Group 2: Pre procedural semithicone administration and Group 3: intraprocedural administration. Mucosal visibility and duodenal motility will be assessed using a scale. Procedure time and endoscopists' satisfaction will be inquired.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

CMH Lahore Medical College

Lahore, Punjab Province, Pakistan

About this study

Study design: This is a randomized, double blind, controlled, trial which will be commenced after ethical approval by the institutional review board at Combined Military Hospital, Lahore. Written informed consent of all participants will be sought. Data will be prospectively collected over a period of 6 months.

Participants: Patients older than 18 years of age, presenting to the Gastroenterology department for an ERCP will be enrolled. Cases that are abandoned due to inability to access the ampulla will be excluded. Patients with grossly altered anatomy resulting in extended procedure time will also excluded.

Study Protocol: Patients will randomly assigned to one of three groups at presentation: The control group (Group 1), the pre-procedure treatment group (Group 2) and the intraprocedural treatment group (Group 3).

Patients will be randomized into three groups using block randomization. A 1:1:1 block randomization technique will be used with block sizes of 6. The random allocation sequence is generated using the randomization website https://www.sealedenvelope.com. A designated nurse shall allot the patients into the specific groups.

All procedures will be performed by two experienced endoscopists (MH and RD) using a side viewing duodenoscope. Each biliary cannulation will be attempted using a sphincterotome and 0.035" guidewire. Still images and high-quality videos will be recorded during the procedure and examined at the end of the procedure by a Hepatology fellow (MS) who is blinded to the treatment arm. The fellow shall grade the mucosal visibility and duodenal contractility using scales employed by previous studies

The four-point scale for mucosal visibility is as follows:

(0) No bubbles-the procedure could be easily performed.

  • Very few bubbles-this did not interfere with the procedure.
  • A slightly greater quantity of bubbles-the procedure could be performed with some difficulty.
  • A large quantity of bubbles interfering with the procedure-accurate evaluation was impossible.

The duodenal motility was graded as follows:

(0) No contractions were observed.

  • <5 contractions per minute were observed.
  • 5 to 10 contractions per minute were observed.
  • 11 to 15 contractions per minute were observed.
  • Continuous contractions were observed. At the end of the procedure, the endoscopist satisfaction will be inquired and rated as good, moderate or poor. The total procedural time will also be recorded.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients presenting for ERCP older than 18years of age.
  • Patients willing to participate in the study, meeting criteria No. 1

Exclusion criteria

  • Cases that are abandoned due to inability to access the ampulla
  • Patients with grossly altered anatomy resulting in extended procedure time

Treatment and study plan

Preprocedural

Drug
  • Oral Semithicone 40mg + Dicyclomine 1mg (30min before procedure) 2. Intraprocedural water Spray

Intraprocedural

Drug
  • Oral Water 30mL (30min before procedure)
  • Simethicone+ Dicylomine spray

Control

Other
  • Oral Water 30mL (30min before procedure) +
  • Intraprocedural Water Spray

Primary outcomes

  1. Duodenal Motility

    Time frame: From enrollment to end of the procedure i.e.: approximately 25 minutes

    The duodenal motility was graded as follows (0) No contractions were observed.

    • <5 contractions per minute were observed.
    • 5 to 10 contractions per minute were observed.
    • 11 to 15 contractions per minute were observed.
    • Continuous contractions were observed.
  2. Mucosal Visibility

    Time frame: From enrollment to end of the procedure i.e.: approximately 25 minutes

    assessed using a 4 point scale as follows

    (0) No bubbles-the procedure could be easily performed.

    • Very few bubbles-this did not interfere with the procedure.
    • A slightly greater quantity of bubbles-the procedure could be performed with some difficulty.
    • A large quantity of bubbles interfering with the procedure-accurate evaluation was impossible.

Secondary outcomes

  1. Endoscopists Satisfaction

    Time frame: From enrollment to end of the procedure i.e.: approximately 25 minutes

    rated as good, moderate or poor.

  2. Time of the procedure

    Time frame: Total procedural length approximately 25 to 45 minutes

    Total duration

Sponsors and collaborators

Lead sponsor

CMH Lahore Medical College and Institute of Dentistry

Other

Registry information

Acronym: SemInERCP

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 10, 2026
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.